Symptomatic HIV CNS viral escape among patients on effective cART.
Adult
Anti-HIV Agents
/ therapeutic use
Antiretroviral Therapy, Highly Active
Central Nervous System Viral Diseases
/ drug therapy
Encephalitis
/ drug therapy
Female
HIV Infections
/ complications
Humans
India
Lamivudine
/ therapeutic use
Lopinavir
/ therapeutic use
Male
Plasma
Retrospective Studies
Viral Load
Cerebral penetration effectiveness score
Cognitive decline HIV
HIV viral escape CNS
Symptomatic CNS escape
Journal
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
received:
23
01
2019
revised:
18
03
2019
accepted:
28
03
2019
pubmed:
6
4
2019
medline:
21
8
2019
entrez:
6
4
2019
Statut:
ppublish
Résumé
The clinical syndrome in symptomatic HIV associated CNS viral escape is poorly defined. We attempted to describe the clinical syndrome, laboratory profile, radiological features and outcomes of HIV infected patients with symptomatic central nervous system (CNS) viral escape in our study. This is a retrospective study were adult patients with HIV infection on cART admitted with a diagnosis of CD8 encephalitis or CNS viral escape in a large teaching hospital in South India was identified. The mean age of the eleven patients included in the study was 37.5 years. Most patients had received almost a decade of antiretroviral treatment at diagnosis (mean: 11.18 years). All patients presented with global cerebral syndrome. Cognitive decline, tremors, and headaches were common manifestations. All patients had lymphocytic pleocytosis (mean cell count: 44.63 cells/ml; lymphocyte percentage: 94.81%) with elevated protein (mean: 125.36 mg/dl). All patients were on boosted protease inhibitors (81.8% on Atazanavir and 18.18% Lopinavir). All except one patient was on Tenofovir and lamivudine combination therapy. White matter changes and deep brain nuclei involvement were common. Most patients required a change of cART to regimens with better CNS penetration and suppression of the resistant virus in the plasma and improved. CNS viral escape should be considered as a differential among patients on Atazanavir presenting with non-focal cerebral syndrome and CSF lymphocytic pleocytosis.
Identifiants
pubmed: 30951880
pii: S1201-9712(19)30162-6
doi: 10.1016/j.ijid.2019.03.033
pii:
doi:
Substances chimiques
Anti-HIV Agents
0
Lopinavir
2494G1JF75
Lamivudine
2T8Q726O95
Types de publication
Journal Article
Langues
eng
Pagination
39-43Informations de copyright
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.